Literature DB >> 10888657

Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

J Glamann1, V M Hirsch.   

Abstract

A potent neutralizing Fab fragment from a long-term survivor of simian immunodeficiency virus (SIVsm) infection was used to construct a recombinant macaque immunoglobulin G1kappa (IgG1kappa) molecule, designated IgG1-201. A Chinese hamster ovary cell line expressing IgG1-201 was derived by stable transfection and optimized for antibody secretion by methotrexate selection and dihydrofolate reductase gene amplification. IgG1-201 effectively neutralized the homologous, molecularly cloned SIVsmH4 virus but had no activity against the heterologous SIVmac251/BK28 virus. The previously characterized, neutralization-resistant SIVsmE543-3 virus was also not neutralized by IgG1-201. Binding to SIVsmH4 gp120 was enhanced in the presence of recombinant soluble CD4, suggesting that IgG1-201 bound a CD4-induced epitope. IgG1-201 immunoprecipitated the SIVsmH4 but not the SIVsmE543-3 envelope despite a close relationship between these two clones. Immunoprecipitation of a panel of SIVsmH4/SIVsmE543-3 chimeric viruses tentatively assigned the neutralization epitope to the third constant domain, immediately C terminal to the V3 loop. These findings suggest the presence of at least one CD4-induced neutralization epitope on SIV, as is the case with human immunodeficiency virus type 1.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10888657      PMCID： PMC112235          DOI： 10.1128/jvi.74.15.7158-7163.2000

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  43 in total

1.  Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251.

Authors:  K A Kent; P Kitchin; K H Mills; M Page; F Taffs; T Corcoran; P Silvera; B Flanagan; C Powell; J Rose
Journal:  AIDS Res Hum Retroviruses       Date:  1994-02       Impact factor: 2.205

2.  Cloning and sequence analysis of kappa and gamma cynomolgus monkey immunoglobulin cDNAs.

Authors:  A P Lewis; K A Barber; H J Cooper; M J Sims; J Worden; J S Crowe
Journal:  Dev Comp Immunol       Date:  1993 Nov-Dec       Impact factor: 3.636

3.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

4.  Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.

Authors:  M C Gauduin; G P Allaway; P J Maddon; C F Barbas; D R Burton; R A Koup
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

5.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

6.  Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.

Authors:  M G Lewis; W R Elkins; F E McCutchan; R E Benveniste; C Y Lai; D C Montefiori; D S Burke; G A Eddy; A Shafferman
Journal:  Vaccine       Date:  1993-10       Impact factor: 3.641

Review 7.  Production of monoclonal antibodies in COS and CHO cells.

Authors:  J J Trill; A R Shatzman; S Ganguly
Journal:  Curr Opin Biotechnol       Date:  1995-10       Impact factor: 9.740

8.  Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

Authors:  P W Parren; H J Ditzel; R J Gulizia; J M Binley; C F Barbas; D R Burton; D E Mosier
Journal:  AIDS       Date:  1995-06       Impact factor: 4.177

9.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity.

Authors:  W S Choi; C Collignon; C Thiriart; D P Burns; E J Stott; K A Kent; R C Desrosiers
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103
View more
  7 in total

1.  Infectious molecular clones from a simian immunodeficiency virus-infected rapid-progressor (RP) macaque: evidence of differential selection of RP-specific envelope mutations in vitro and in vivo.

Authors:  Takeo Kuwata; Houman Dehghani; Charles R Brown; Ronald Plishka; Alicia Buckler-White; Tatsuhiko Igarashi; Joseph Mattapallil; Mario Roederer; Vanessa M Hirsch
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions.

Authors:  Franco Scinicariello; Carrie N Engleman; Lakshmi Jayashankar; Harold M McClure; Roberta Attanasio
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

3.  A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses.

Authors:  Takeo Kuwata; Russell Byrum; Sonya Whitted; Robert Goeken; Alicia Buckler-White; Ronald Plishka; Ranjini Iyengar; Vanessa M Hirsch
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

4.  Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression.

Authors:  Jenny A Greig; Hui Peng; Jason Ohlstein; C Angelica Medina-Jaszek; Omua Ahonkhai; Anne Mentzinger; Rebecca L Grant; Soumitra Roy; Shu-Jen Chen; Peter Bell; Anna P Tretiakova; James M Wilson
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

5.  Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses.

Authors:  Austin W Boesch; Nana Yaw Osei-Owusu; Andrew R Crowley; Thach H Chu; Ying N Chan; Joshua A Weiner; Pranay Bharadwaj; Rufus Hards; Mark E Adamo; Scott A Gerber; Sarah L Cocklin; Joern E Schmitz; Adam R Miles; Joshua W Eckman; Aaron J Belli; Keith A Reimann; Margaret E Ackerman
Journal:  Front Immunol       Date:  2016-12-13       Impact factor: 7.561

Review 6.  Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.

Authors:  Jody D Berry
Journal:  Vet J       Date:  2005-09       Impact factor: 2.688

7.  Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia.

Authors:  Lili Wang; Ilayaraja Muthuramu; Suryanarayan Somanathan; Hong Zhang; Peter Bell; Zhenning He; Hongwei Yu; Yanqing Zhu; Anna P Tretiakova; James M Wilson
Journal:  Mol Ther Methods Clin Dev       Date:  2021-05-05       Impact factor: 6.698
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.